NCX4016: a novel antithrombotic agent

Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents. Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential. Nitroaspirin in vitro inhi...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease 2003-05, Vol.35, p.S20-S26
Main Authors: Gresele, P, Momi, S, Mezzasoma, A.M
Format: Article
Language:English
Subjects:
Animals
Antithrombotic agents
Aspirin
Aspirin - analogs & derivatives
Aspirin - pharmacology
Blood Platelets - drug effects
Disease Models, Animal
Fibrinolytic Agents - pharmacology
Humans
In Vitro Techniques
Mice
Monocytes - drug effects
Nitric oxide
Nitric Oxide - pharmacology
Nitroaspirin
Platelet Aggregation Inhibitors - pharmacology
Pulmonary Embolism - drug therapy
Rabbits
Rats
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents. Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential. Nitroaspirin in vitro inhibits platelet aggregation and adhesion under shear conditions and smooth muscle cell proliferation—all activities not exerted by aspirin. In vivo nitroaspirin exerts antithrombotic properties and prevents restenosis in hypercholesterolemic mice while aspirin is inactive. Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment.
ISSN:1590-8658
1878-3562
DOI:10.1016/S1590-8658(03)00048-3